Soleno Therapeutics Inc
F:6XC1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Soleno Therapeutics Inc
F:6XC1
|
US |
|
K
|
Kering SA
DUS:PPX
|
FR |
|
Viasat Inc
NASDAQ:VSAT
|
US |
|
I
|
Innocan Pharma Corp
XHAM:IP4
|
IL |
|
S
|
Sicily By Car SpA
MIL:SBC
|
IT |
|
KRBL Ltd
BSE:530813
|
IN |
|
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
|
US |
|
D
|
Devon Energy Corp
F:DY6
|
US |
|
G
|
Givaudan SA
DUS:GIN
|
CH |
Wall St Price Targets
6XC1 Price Targets Summary
Soleno Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 6XC1 is 0.169 EUR with a low forecast of 0.158 EUR and a high forecast of 0.247 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 6XC1's stock price target?
Price Target
0.169
EUR
According to Wall Street analysts, the average 1-year price target for 6XC1 is 0.169 EUR with a low forecast of 0.158 EUR and a high forecast of 0.247 EUR.
What is the Revenue forecast for Soleno Therapeutics Inc?
Projected CAGR
75%
Over the last 12 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 3 years is 75%.
What is the Gross Profit forecast for Soleno Therapeutics Inc?
Projected CAGR
71%
The compound annual growth rate for Gross Profit over the next 3 years is 71%.
What is the Operating Income forecast for Soleno Therapeutics Inc?
Projected CAGR
307%
The compound annual growth rate for Operating Income over the next 3 years is 307%.
What is the Pre-Tax Income forecast for Soleno Therapeutics Inc?
Projected CAGR
216%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 216%.
What is the Net Income forecast for Soleno Therapeutics Inc?
Projected CAGR
197%
The compound annual growth rate for Net Income over the next 3 years is 197%.
